Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Quanterix Corp (NQ: QTRX )

15.07 +0.22 (+1.48%)
Streaming Delayed Price Updated: 11:52 AM EDT, Jul 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 48,404
Open 14.97
Bid (Size) 15.04 (4)
Ask (Size) 15.13 (2)
Prev. Close 14.85
Today's Range 14.88 - 15.30
52wk Range 11.82 - 29.70
Shares Outstanding 38,063,618
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Quanterix Presents Data Demonstrating Successful Multi-Marker Approach for Alzheimer’s Disease Detection that is More Effective than Standalone Plasma p-Tau 217
From Quanterix Corporation
Via Business Wire
Quanterix to Participate at the Scotiabank Healthcare 1x1 Day
From Quanterix Corporation
Via Business Wire

Performance

YTD
-44.49%
-44.49%
1 Month
+18.85%
+18.85%
3 Month
-6.51%
-6.51%
6 Month
-34.22%
-34.22%
1 Year
-39.33%
-39.33%

More News

Read More
Quanterix to Present at 45th Annual Goldman Sachs Global Healthcare Conference
From Quanterix Corporation
Via Business Wire
Quanterix Corp. (NASDAQ: QTRX) Highlighted for Surprising Price Action
Via Investor Brand Network
Quanterix to Present at Leerink Partners Healthcare Crossroads Conference 2024
From Quanterix Corporation
Via Business Wire
QTRX Stock Earnings: Quanterix Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Quanterix Releases Financial Results for the First Quarter of 2024
From Quanterix Corporation
Via Business Wire
Quanterix To Report First Quarter 2024 Financial Results
From Quanterix Corporation
Via Business Wire
Earnings Scheduled For February 29, 2024
Via Benzinga
Earnings Preview: Quanterix
Via Benzinga
Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer’s Disease Testing Infrastructure
From Quanterix
Via Business Wire
Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease
From Quanterix Corporation
Via Business Wire
Quanterix Releases Operating Results for Fourth Quarter and Full Year 2023
From Quanterix Corporation
Via Business Wire
Earnings Scheduled For February 27, 2024
Via Benzinga
A Preview Of Quanterix's Earnings
Via Benzinga
Earnings Outlook For Quanterix
Via Benzinga
Quanterix Reschedules Q4 and Full Year 2023 Earnings Conference Call; Reaffirms 2023 Guidance
From Quanterix Corporation
Via Business Wire
Quanterix Announces First Collaborations with Five Health Networks to Aid the Diagnosis and Clinical Management of Individuals with Alzheimer’s Disease
From Quanterix Corporation
Via Business Wire
Quanterix to Present at Cowen’s 44th Annual Health Care Conference
From Quanterix Corporation
Via Business Wire
Earnings Scheduled For February 26, 2024
Via Benzinga
Quanterix Fourth Quarter Earnings and Full Year 2023 Financial Results Conference Call
From Quanterix Corporation
Via Business Wire
Quanterix to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Quanterix Corporation
Via Business Wire
Quanterix To Participate at The Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
From Quanterix Corporation
Via Business Wire
Sotera Health Appoints Karen Flynn to Board of Directors
From Sotera Health Services, LLC
Via GlobeNewswire
Quanterix Releases Operating Results for Third Quarter 2023
From Quanterix Corporation
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.